Patents
Patent Number: 7,465,582
Various organs have regenerative capabilities, which are believed to occur as a result of endogenous stem cells or progenitor cells. This has been described in the
liver,
pancreas,
heart, and even
brain. Although there is controversy as to whether the tissue specific...
Inventors: Arenas; Ernest (Stockholm, SE), Perlmann; Thomas (Sollentuna, SE), Snyder; Evan Y. (Boston, MA), Wagner; Joseph (West Chester, PA), Akerud; Peter (Stockholm, SE)
Assignee: Neuro Therapeutics AB (Stockholm, SE)
Date of First Priority Issue: Thursday April 27th, 2000
Patent Number: 7,462,602
Bone marrow stem cells have been demonstrated to have some degree of anti-fibrotic effect. For example, after myocardial infarct, bone marrow infusion has been demonstrated to
decrease non-viable myocardial scar tissue formation. Additionally, bone marrow administration has been effective in pilot trials of
hepatic fibrosisInventors: Schultz; Gregory S. (Gainesville, FL), Lewin; Alfred S. (Gainesville, FL), Blalock; Timothy D. (Boston, MA)
Assignee: University of Florida Research Foundation, Inc. (Gainesville, FL)
Date of First Priority Issue: Thursday May 1st, 2003
Patent Number: 7,459,307
Cord blood derived stem cells represent a potent source of young, pluripotent, cells. Although previously their use was restricted to hematological malignancies, newer studies have demonstrated cord blood cells may be useful for many regenerative purposes, such as Ethicon's patent #
7,413,734 which teaches use of cord blood stem cells for treatment of...
Inventors: Ha; Chul-Won (135-785 Seoul, KR), Yang; Yoon-Sun (Seoul, KR), Yang; Sung-Eun (Seoul, KR)
Assignee: Medipost Co., Ltd (Seoul, KR)
Date of First Priority Issue: Tuesday August 14th, 2001
Patent Number: 7,459,541
This patent covers a series of fusion proteins that are generated with selectively to bind collagen. The inventors believe that since various forms of collagen are exposed during injury, the specific targeting of "repair" proteins to the injuried tissue will augment the healing process. Specifically the inventors target the "repair proteins": insulin, nerve growth...
Inventors: Hall; Frederick L. (Glendale, CA), Gordon; Erlinda M. (Glendale, CA), Beart; Robert W. (Pasadena, CA), Nimni; Marcel (Santa Monica, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Wednesday July 21st, 1999
Patent Number: 7,459,152
The non-hematological uses of erthrypoietin are very interesting. Studies have demonstrated that erythropoietin can accelerate cardiac healing after infarct, or even have a therapeutic effect on stroke. The current patent teaches that erythropoietin may be used in conjunction with transplantation of dopaminergic cells in the treatment of Parkinson's Disease. Essentially it states...
Inventors: Sortwell; Caryl E. (Chicago, IL), Collier; Timothy J. (Deerfield, IL)
Assignee: Rush University Medical Center (Chicago, IL)
Date of First Priority Issue: Wednesday April 23rd, 2003
Patent Number: 7,456,333
Chronic myeloid leukemia is characterized by a chromosomal translocation resulting in production of the
bcr-abl fusion protein, which is believed to be responsible for initiation of the malignancy. Vaccination against
bcr-abl peptides has been associated with some clinical benefit, and small molecule targeting of this protein has...
Inventors: Garcia; Isidro Sanchez (Salamanca, ES), Losada; Jesus Perez (Salamanca, ES)
Assignee: Universidad de Salamanca (Salamanca, ES); Consejo Superior de Investigaciones (Madrid, ES)
Date of First Priority Issue: Tuesday November 27th, 2001
Patent Number: 7,455,983
One of the issues of embryonic stem cell therapeutics development is the relative lack of methods for expanding them without inducing their differentiation. Various methodologies are known in the art, for example use of
different feeder layers or
speciality media. The current patent is very...
Inventors: Xu; Chunhui (Palo Alto, CA), Li; Yan (Menlo Park, CA), Mandalam; Ramkumar (Union City, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Monday January 10th, 2000
Patent Number: 7,455,962
Therapeutic angiogenesis offers the possibility of treating a variety of diseases associated with ischemia. For example, autologous bone marrow stem cells were used at Indiana University for the treatment of
critical limb ischemia patients. Although several studies have used various
bone marrow and bone marrow derived...
Inventors: Miyajima; Atsushi (Tokyo, JP), Hara; Takahiko (Chiba, JP)
Assignee: Toudai TLO. Ltd. (Tokyo, JP)
Date of First Priority Issue: Wednesday November 10th, 1999
Patent Number: 7,452,718
One of the important areas of research in embryonic stem cells involves design of novel ways to upscale production of differentiated cells. Another important area is developing cells that may be used clinically. The company Novocell, for example, has developed various systems of expanding embryonic stem cells
without the use of mouse feeder... Inventors: Gold; Joseph D. (San Francisco, CA), Hassanipour; Mohammad (Danville, CA), Collins; Lila R. (Fremont, CA), Xu; Chunhui (Palo Alto, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Friday March 26th, 2004
Patent Number: 7,452,532
Stem cell therapy for treatment of myocardial infarctions has demonstrated some benefit, including in double blind trials. Although the exact mechanism of action is unknown, some groups suggest that
bone marrow stem cells can differentiate directly into new cardiomyocytes, whereas others believe the injected stem cells release
Inventors: Alt; Eckhard (Ottobrunn, DE)